Comparison of 8 weeks standard treatment (rifampicin plus clarithromycin) vs. 4 weeks standard plus amoxicillin/clavulanate treatment [RC8 vs. RCA4] to shorten Buruli ulcer disease therapy (the BLMs4BU trial): study protocol for a randomized controlled multi-centre trial in Benin

BACKGROUND: Buruli ulcer (BU) is a neglected tropical disease caused by Mycobacterium ulcerans that affects skin, soft tissues, and bones, causing long-term morbidity, stigma, and disability. The recommended treatment for BU requires 8 weeks of daily rifampicin and clarithromycin together with wound...

Descripción completa

Detalles Bibliográficos
Autores principales: Johnson, Roch Christian, Sáez-López, Emma, Anagonou, Esaï Sèdjro, Kpoton, Godwin Gérard, Ayelo, Adjimon Gilbert, Gnimavo, Ronald Sètondji, Mignanwande, Franck Zinsou, Houezo, Jean-Gabin, Sopoh, Ghislain Emmanuel, Addo, Juliet, Orford, Lindsay, Vlasakakis, Georgios, Biswas, Nandita, Calderon, Felix, Della Pasqua, Oscar, Gine-March, Anna, Herrador, Zaida, Mendoza-Losana, Alfonso, Díez, Gabriel, Cruz, Israel, Ramón-García, Santiago
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9270751/
https://www.ncbi.nlm.nih.gov/pubmed/35804454
http://dx.doi.org/10.1186/s13063-022-06473-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9270751/
https://www.ncbi.nlm.nih.gov/pubmed/35804454
http://dx.doi.org/10.1186/s13063-022-06473-9

Ejemplares similares